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Summary 
We established six T cell clones specific for pyruvate dehydrogenase complex (PDC)-E2 peptides 
from four different patients with primary biliary cirrhosis using 33 different peptides of 17-20 
amino acid residues corresponding to human PDC-E2  as stimulating antigens. The minimal 
T  cell epitopes of these six T  cell clones were all mapped to the same region of the PDC-E2 
peptide 163-176 (GDLLAEIETDKATI), which corresponds to the inner lipoyl domain of PDC- 
E2. The HLA restriction molecules for this epitope were all identified as HLA DRB4 0101. 
The common essential  amino acids  of this epitope for these T  cell clones were E, D, and K 
at positions 170, 172, and 173, respectively; other crucial amino acids for this epitope differed 
in each T cell clone. In addition, the alanine-substituted peptides at positions 170 and 173, but 
not 172, inhibited the proliferation of all T cell clones induced by the original peptide of human 
PDC~E2 163-176, indicating that amino acid D  at position 172 is a critical MHC~binding site 
for all T  cell clones tested.  Interestingly, all T  cell clones reacted to  PDC-E2 peptide 36-49 
(GDLIAEVETDKATV),  which corresponds to the outer lipoyl domain of human PDC-E2. 
Furthermore, one T cell clone cross-reacted with exogenous antigens such as Escherichia coli PDC-E2 
peptide 31-44/134-147/235-248  (EQSLITVEGDKASM), which has an EXDK sequence. This 
is a definite demonstration of the presence of molecular mimicry at the T  cell clonal level in 
human autoimmune diseases. It is also considered possible to design peptide-specific immunotherapy 
based on the findings of T  cell autoepitopes in primary biliary cirrhosis. 
p rimary  biliary  cirrhosis  (PBC) 1  is  an  autoimmune 
chronic cholestatic liver disease characterized by the pres- 
ence of antimitochondrial antibodies (AMAs) and inflamma- 
tion of interlobular bile ducts in the liver (1). PBC affects 
mainly women and ultimately leads to liver failure (2). The 
major mitochondrial antigens (Ags) recognized by AMAs 
have recently been identified as E2 components of 2-oxo acid 
dehydrogenase complexes; pyruvate dehydrogenase complex 
(PDC), 2-oxoglutarate dehydrogenase complex (OGDC), and 
branched chain 2-oxo acid dehydrogenase complex (BCO- 
ADC) that are localized in the mitochondrial inner mem- 
brane (3-9). Immunohistochemical examinations of the lym- 
phocytes infiltrating the portal tracts of livers of PBC patients 
1  Abhreviations used in this  paper: Ag, antigen; APC, antigen-presenting  cell; 
AMA, antimitochondrial  antibody;  BCOADC, branched  chain  2-oxo acid 
dehydrogenase  complex;  OGDC, 2-oxoglutarate  dehydrogenase  complex; 
PBC, primary  biliary  cirrhosis; PDC, pyruvate  dehydrogenase  complex; 
PDC-E2, E2 component of PDC; SI, stimulation index; SP, synthetic 
peptide. 
revealed a predominance of activated CD8 § T cells, as well 
as CD4 + T cells, with B and NK cells (10-12).  By fluores- 
cence microscopy, it has been demonstrated that large amount 
of Ags immunoreactive with AMAs are present on the sur- 
face of biliary epithelial cells in the livers of PBC patients 
(13-15).  Furthermore, bile duct epithelia and hepatocytes in 
PBC express large amounts of HLA class I and II molecules 
(15-17).  These observations suggest that  T  cell-mediated 
mechanisms are involved in the pathogenesis of the destruc- 
tion of bile duct epithelia and hepatocytes in PBC. However, 
thus far little has been reported on the autoepitopes of the 
mitochondrial Ags recognized by T cells in PBC (14, 18-20). 
In other human organ-specific autoimmune diseases, such 
as multiple sclerosis (21-24), chronic thyroiditis (25-28), and 
myasthenia gravis  (29-32),  pathogenic T  cell autoepitopes 
and their restriction molecules of MHC class I or II have 
recently been studied at the molecular level, and some patho- 
genic T  cell autoepitopes have been identified. However, T 
cell autoepitopes remain to be elucidated in most other au- 
toimmune diseases, because of the methodological limitations 
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self Ags. Only some primitive studies concerning the T  cell 
autoepitopes of U1  small nuclear ribonucleoprotein A  pro- 
tein (33) and glutamic acid decarboxylase (34, 35) have been 
previously reported for SLE and insulin-dependent diabetes 
mellitus,  respectively. 
In the present study, we established six T cell clones specific 
for PDC-E2 from the peripheral blood of patient s with PBC. 
Surprisingly, the minimal T cell epitopes of these T cell clones 
from four different patients with PBC were all mapped to 
the same region of PDC-E2 peptide 163-176, which corre- 
sponds to the inner lipoyl domain of human PDC-E2.  Fur- 
thermore, all T  cell clones were restricted by HLA DRB4 
0101.  We also found that there are three common essential 
amino acid residues for this epitope,  EXDK,  and that one 
T  cell clone cross-reacted with the peptide derived from ex- 
ogenous Ags such as E. coli PDC-E2, which has an EXDK 
sequence. 
This is not only a definite demonstration of the T  cell au- 
toepitope of mitochondrial Ags in PBC, but also a demon- 
stration of "molecular mimicry" that is operative at the T 
cell clonal level in human autoimmune diseases. The possible 
mechanism of molecular mimicry at the T  cell clonal level 
is  also discussed. 
Materials  and  Methods 
Patients.  13 patients with PBC of various  histological stages 
(stages I-IV) were studied (age 38-67 yr, mean age 58.7 yr; stage 
I: 4 patients,  stage  II:  7 patients,  stage III:  1 patient,  stage  IV: 
1 patient). The diagnosis of PBC was established based on the criteria 
of the autoimmune hepatitis/primary biliary cirrhosis subgroup, 
which is part of the Intractable Disease  Study Group organized 
by the Ministry of Health and Welfare of Japan (36). 
Preparation of Synthetic Peptides Corresponding to PDC-E2.  40 
different peptides composed of 13-20 amino acid residues corre- 
sponding to the amino acid sequence of human PDC-E2 were syn- 
thesized via F-moc chemistry using a peptide synthesizer (model 
432A Synergy; Applied Biosystems Inc., Foster City, CA) (9, 37). 
The peptides were purified by reverse-phase HPLC, and the purity 
of all peptides used in this study was >95 %, as determined by HPLC 
analysis. The peptides  were designed according to the analysis of 
the amphipathic regions of the antigenic molecules and the pres- 
ence of consensus motifs based on the studies of Berzofsky et al. 
(38). Synthetic peptides (SPs) used in this study, indicated by the 
amino acid  number from the NH2 terminus  of PDC-E2,  were 
classified  into  seven  groups  as  follows:  group  1:  SPs  -40--21, 
-31--12, -17-2, 15-34, and 23-42; group 2: SPs 34-50, 38-56, 69-88, 
80-99, and 137-156; group 3: SPs 144-163, 163-182, 168-187, 182- 
201, and 198-217; group 4: SP 208-227,  255-274,  261-280,  269- 
288,  and 289-306;  group 5: SPs 332-351,  341-360, 355-374,  363- 
382, and 373-392;  group 6: SPs 392-411, 406-425,  449-466,  495- 
514, and 503-522;  and group 7: SPs 521-540,  536-553,  and 543- 
560 (Fig.  1). For fine T  cell epitope mapping, SPs 161-177, 162- 
175, 163-175,  163-176,  163-177,  164-176,  164-177, and 163-182, 
as well as 14 different alanine- or serine-substituted peptides of SP 
163-176 were synthesized. For the cross-reactivity experiments of 
T cell clones, five different peptides corresponding to human PDC- 
E2  peptide  36-49  (GDLIAEVETDKATV),  Pseudomonas putida 
BCOADC  104-117 (DELLATIETDKIDI), E.  coli PDC-E2  31- 
44/134-147/235-248  (EQSLITVEGDKASM),  human  glycogen 
phosphorylase 3 354-367  (LVDLERMDWDKAWD), and HLA 
DR ot chain 82-95 (QGALANIAVDKANL) were synthesized and 
used in a T cell proliferation assay. Purified porcine PDC and OGDC 
were purchased from the Sigma Chemical Co. (St. Louis, MO). 
T  Celt Proliferation Assay.  PBMCs were separated  from the 
peripheral blood by Ficoll-Isopaque gradient centrifugation. T cells 
were purified by rosetting PBMCs with sheep red blood cells. 1 x 
10  s T  cells and 1  x  104 autologous irradiated (3,000 rad) non- 
T cells per well were cultured in the presence of peptide mixtures 
(groups 1-7; each synthetic peptide concentration was 10 #g/ml) 
in a 96-well round bottom plate (Costar Corp., Cambridge, MA) 
in RPMI 1640 supplemented with 2 mM t-glutamine, 50 ng/ml 
of gentamycin, and 10% human AB-positive serum (complete RPMI 
medium) at 37~  in a humidified 5% CO2 atmosphere. In each 
experiment, microcultures containing T cells and irradiated non- 
T cells, but no Ag served as negative controls. More than 30 wells 
were studied in each group. After 7 d of culture, the T cells were 
restimulated with the same concentration of Ag or without Ag 
in the presence of 5  x  10  g freshly prepared,  irradiated  (3,000 tad) 
autologous PBMCs per well. After another 7 d of culture, half 
of the cells in the microculture wells were transferred to other plates 
and were pulsed with [3H]TdR. (0.5/~Ci/well; Amersham Inter- 
national,  UK) for 10 h.  [ZH]TdR incorporation was  measured 
with  a  scintillation  counter (1205 Betaplate liquid scintillation 
counter; Pharmacia, Uppsala, Sweden). The stimulation index (SI) 
was calculated  as follows:  SI  =  the mean value of [3H]TdR. in- 
corporation  (cpm)  in  wells  containing  Ag/the  mean  value  of 
[3H]TdR incorporation (cpm) in wells not containing Ag. Usu- 
ally 20-30 wells were studied for each group. The wells exhibiting 
an SI >2 were determined to be positive  for T cell proliferation. 
Establishment of Ag-specific T  Cell Clones.  The microcultures 
showing positive proliferation were kept in culture in the presence 
of freshly prepared autologous antigen-presenting cells (APCs) in 
complete RPMI medium containing the same peptide mixture (each 
peptide concentration was  10 #g/ml) and 20 U/ml IL-2 (Takeda 
Medical Co., Tokyo, Japan). The cells were repeatedly stimulated 
with the same Ag in the presence of irradiated autologous PBMCs 
every week. After four to five repeated  stimulations, these T cell 
lines were cloned at 0.5 cell per well in complete R.PMI medium 
containing IL-2 (100 U/ml) in the presence of autologous irradi- 
ated (3,000 tad) PBMCs as feeders. The peptide mixture-specific 
T  cell  clones  were expanded and  studied  in  the following ex- 
periments. 
Analysis of the Cell Surface Phenotypes of T  Cell Clones by Flow 
Cytometry.  T cell clones were stained with a variety of FITC- or 
PE-conjugated mAbs, including mAbs to CD3 (anti-Leu4),  CD4 
(anti-Leu32a),  CD8  (anti-Leu2a),  CD45RA  (2H4),  CD45R.O 
(UCHL-1), and TCR.  All of these mAbs were purchased from 
Becton Dickinson Immunocytometry Systems (Mountain View, 
CA). T cell clones were first incubated with an adequate concen- 
tration of these FITC- or PE-conjugated mAbs at 4~  for 30 rain. 
After washing the cells with PBS containing 0.1% sodium azide 
(Sigma Chemical Co.), the cells were analyzed by flow cytometry 
(FACScan|  Becton Dickinson). 
Proliferation oft Cell Clones in Response to Different Concentrations 
of Synthetic Peptide in the Presence or Absence of Various mAbs to Cell 
Surface Molecules.  Synthetic peptide was used at different concen- 
trations (1-20 #g/ml) to study the Ag specificity of the T cell clones. 
The role of cell surface molecules in the T cell proliferative response 
to Ag was also studied using various mAbs: mouse anti-CD3 (anti- 
OKT3), mouse anti-CD4 (anti-OKT4), mouse anti-CD8 (anti- 
OKT8), mouse anti-class I (W6/32), and mouse anti-HLA DP, 
DQ, and DR. (B7/21, Hull, and L243) (all of these mAbs were 
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Figure  1.  Synthetic peptides used for the generation of PDC-E2-specific  T cell clones. The amino acid sequences of PDC-E2 are based on the report 
by Coppel et al. (5). Synthetic peptides, which are indicated by the amino acid number from the NH2 terminus of PDC-E2, were classified into seven 
groups as described in Materials and Methods. 
kindly provided by Dr. T. Sasazuki, Division of Genetics,  Medical 
Institute ofBioregulation, Kyushu University, Kyushu, Japan). 5 x 
104 T  cells were seeded  in  a 96-well,  round-bottom plate con- 
taining 5  x  104 irradiated (3,000 rad)  autologous PBMCs and 
synthetic peptide in the presence or absence of various mAbs.  All 
mAbs were used at a 1:100 dilution of ascites. After 3 d of culture, 
a T cell proliferation assay was similarly performed in triplicate as 
previously described. 
Determination of the Critical Amino Acids of T Cell Epitopes  for 
the Recognition by TCR or  for the Binding to HLA DR Using Alanine- 
or Serine-substituted  Peptides of  SP 163-176.  To determine the amino 
acids of SP 163-176 critical for the recognition by TCR (epitope) 
or for the binding to HLA (anchor), five T cell clones specific for 
SP 163-176 were studied for their proliferative response to alanine- 
or serine-substituted peptides of SP 163-176. In some experiments, 
alanine-  or serine-substituted peptides were used as competitors 
for the original peptide 163-176 in a T  cell proliferation assay. 
PCR-based DNA  Typing of HLA  Class II Genes.  The DNA 
typing of HLA class II genes was performed using a PCR/sequence- 
specific oligonucleotide probe (SSOP) analysis in 13 PBC patients 
and 7 healthy subjects as described elsewhere (39). Genomic DNA 
was extracted from peripheral granulocytes and subjected to PCR. 
in  10 mM  Tris-HC1  (pH  8.4  at  24~  50 mM  KC1, 2.0 mM 
MgClz, 0.1 mg/ml gelatin, 0.02% NP-40 to amplify the second 
exons of the DR.B1, DQA1, DQB1, DPA1, or DPB1 genes, using 
thermostable DNA polymerase. Amplified DNA was spotted onto 
a nylon membrane (Hybond N +; Amersham International), and 
it was immobilized by alkaline denaturation in 0.4 N NaOH. The 
hybridization procedure with 140 types of SSOPs has been described 
previously (39). 11 positive hybridization signals were obtained by 
exposing the filters to x-ray film (XAR-5; Eastman Kodak Co., 
Rochester, NY) at room temperature for 30 min. 
Results 
Proliferative Response of T  Cells to Synthetic  Peptides Corre- 
sponding to Human PDC-E2.  We studied the T  cell prolifer- 
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alive response to synthetic peptides corresponding to puta- 
tive T  cell epitopes of human PDC-E2 (Fig. 1). The T  cells 
derived from the majority of patients with PBC proliferated 
in response to synthetic peptide groups 2, 3, and 6 (the mean 
values  __  SD of stimulation indices ranged from 1.9  +_  0.4 
to 2.6  _  0.9), but not to groups  1,  4,  5,  and 7  (the mean 
values  +__ SD of stimulation indices ranged from 1.0  _+  0.2 
to  1.4  _  0.4). 
Generation and Characterization of T  Cell Clones Specific for 
Peptides Corresponding to Human PDC-E2.  Microcultures that 
were stimulated  by peptide mixture  group  2,  3,  or 6  and 
showed a value of [3H]TdR incorporation two times higher 
than the mean value of microcultures without any peptides 
were repeatedly stimulated with the same group of peptide 
mixtures (group 2, 3, or 6) in the presence of irradiated au- 
tologous PBMCs and IL-2 (20 U/ml) once every week. After 
four to five repeated stimulations, the T cell lines were cloned 
at  0.5  cell  per  well.  Consequently,  six T  cell  clones  that 
proliferated in response to peptide mixture group 3 were ob- 
tained from four different patients  (Table 1).  These T  cell 
clones responded to SP 163-182, but not to other peptides 
contained in the group 3 peptide mixture (Fig. 2). Whereas 
all T  cell clones proliferated in a dose-dependent manner in 
response to SP 163-182  (Fig. 3), they did not proliferate in 
response  to  other Ags,  such as  OVA  or OGDC.  Further- 
more, the proliferation of these peptide-specific T  cell clones 
was  inhibited by mAbs  such  as  anti-CD3,  anti-CD4,  and 
anti-HLA DR  (Fig. 3). The surface phenotypes of these T 
cell clones were CD3 +, CD4 +, CD45RO +, and TCRot~ +, 
as determined by a flow cytometric analysis  (Table 1). 
HLA Restriction ofT Cell Clones Specific  for SP 163-182.  To 
identify the HLA molecules responsible for Ag presentation 
of SP 163-182 to T  cell clones, we used allogeneic irradiated 
PBMCs with various HLA haplotypes as APCs. Briefly, the 
irradiated  allogeneic PBMCs  (5  x  104 per well)  and  each Table  1.  List of T  Cell Clones Specific for Human PDC-E2 Generated in the Present Study 
HLA 
Donor  T  cell clones  Peptide specificity  SI*  restrictiont  Surface Markers 
Patient 2  T-pep-2-1  PDC-E2  163-182  48.2  DR  CD3 CD4 CD45RO  TCRct/3 
T-pep-2-2  PDC-E2  163-182  49.1  DR  CD3 CD4 CD45RO  TCRo~/3 
T-pep-8-1  PDC-E2  163-182  19.8  DR  CD3 CD4 CD45RO  TCRol/8 
T-pep-10-1  PDC-E2  163-182  15.1  DR  CD3 CD4 CD45RO  TCRo~/3 
T-pep-11-1  PDC-E2  163-182  39.1  DR  CD3 CD4 CD45RO  TCRo~/8 
T-pep-11-2  PDC-E2  163-182  82.3  DR  CD3 CD4 CD45RO  TCRo~/3 
Patient 8 
Patient  10 
Patient  11 
* Stimulation index (SI) was calculated as described in Materials and Methods. 
* HLA restriction was studied using mAbs: mouse anti-CD3 (anti-OKT3), mouse anti-CD4 (anti-OKT4), mouse anti-CD8 (anti-OKTS), mouse 
anti-class I (W6/32), and mouse anti-HLA DP, DQ, and DR (B7/21, Hull, and L243). 
S Cell surface markers were studied using FITC- or PE-conjugated mAbs, including mAbs to CD3 (anti-Leu4): CD4 (anti-Leu32a), CD8 (anti- 
Leu2a), CD45RA  (2H4), CD45R.O (UCHL-1), and TCR. 
T  cell clone (5  x  104 per well) were cocultured in the pres- 
ence of Ag for 3 d.  [3H]TdR (0.5 #Ci/well) was pulsed for 
the last 10 h and the [3H]TdR. incorporation was measured. 
Each assay was performed in triplicate.  We also studied the 
genomic type of HLA class II in four patients with PBC who 
were the donors of peptide-specific T  cell clones (patient 2: 
HLA DRB1 0410 1501 DRB4 0101 DRB5 0101; patient 8: 
HLA DRB1 0405 0803 DRB4 0101; patient 10: HLA DRB1 
0405 0901 DRB4 0101;  and patient  11: HLA DRB1  0901 
1302 DRB3  0301 DRB4 0101), as well as in seven healthy 
subjects  (Fig.  4).  All  T  cell  clones,  including  T-pep-2-1, 
responded to SP 163-182 presented by allogeneic PBMCs de- 
rived from S.S., T.M., K.H., E.B., N.F.,  and H.I., but not 
from K.Y. (Fig. 4). The common HLA class II genotype shared 
by patients  2, 8,  10,  and  11, as well as healthy subjects, ex- 
cept for K.Y.,  was  only HLA DRB4  0101  (data of DP or 
T-pep-2-1 
NO Antigen 
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Figure 2.  The peptide specificity  of T cell clones specific  for PDC-E2 
peptide mixture group 3. T cells that showed a significant proliferation 
to peptide mixtures (group 2, 3, or 6) were repeatedly stimulated with 
the same peptide mixtures in the presence  of irradiated autologous PBMCs 
and IL-2 (20 U/m1). After four to five repeated stimulations, the T cells 
were cloned at 0.5 cell per well. Six T cell clones specific for PDC-E2 
peptide mixture group 3 were obtained from four different patients with 
PBC. These T cell clones were tested for their proliferative  response to 
each peptide (SPs 144-163, 163-182, 168-187, 182-201, and 198-217) by 
a [3H]TdR incorporation assay. All of the T cell clones reacted to SP 163- 
182, but to none of the other peptides. 
DQ  allele; not shown),  indicating  that  these T  cell clones 
recognized SP 163-182 in the context of HLA DRB4 0101. 
Minimal Epitope Mapping ofT Cell Clones Specific  for PDC- 
E2.  Next, minimal epitope mapping of T cell clones specific 
for SP 163-182 was performed using eight different peptides 
composed of 13-20 amino  acids residues corresponding to 
PDC-E2  163-182 (SPs  162-175,  163-175,  164-177,  164-176, 
163-176,  163-177,  161-177 and  163-182). As shown in Fig. 
5,  all T  cell clones, including T-pep-2-1, proliferated in re- 
sponse to SP 163-176, but they did not proliferate in response 
to SP 164-176 or SP 163-175, indicating that the 14-amino 
acid sequence of PDC-E2 163-176 (GDLLAEIETDKATI) is 
the minimum T  cell epitope in the context of HLA DRB4 
0101. 
Determination of  Amino Acids Critical  for Recognition by TCR 
or for Binding to HLA DRB4 0101 Using Alanine-  or Serine- 
substituted Peptides of SP 163-176. As shown  in  Figs.  6  and 
7, alanine- or serine-substituted SP 163-176 at position 165, 
166,  167,  168,  170,  172, or 173 abrogated the proliferative 
response of the T cell clone T-pep-2-1. Alanine or serine sub- 
stitution  at position  166,  167,  168,  170,  171,  172,  or  173 
abrogated the proliferative response of clone T-pep-2-2. Ala- 
nine substitution at position 166, 170, 172, or 173 abrogated 
the proliferative response of clone T-pep-10-1. Whereas ala- 
nine substitution at only three positions- 170, 172, or 173- 
abrogated the proliferative response of clone T-pep-11-1, ala- 
nine substitution at position 169, 170, 172, or 173 abrogated 
the proliferative response of clone T-pep-11-2. These results 
indicate that  the common essential amino  acids for MHC 
or TCR binding of SP 163-176 are E, D, and K  at positions 
170,  172,  and  173,  respectively. In addition,  the results of 
the competition experiments for antigen presentation between 
nonstimulatory single alanine- or serine-substituted peptide 
analogues and SP 163-176 are shown in Fig. 8. The preincu- 
bation of T-pep-2-2 with alanine- or serine-substituted pep- 
tides of SP 163-176 at position 166,  167,  168,  170,  171,  or 
173 inhibited  the proliferative response of clone T-pep-2-2 
in response to the original peptide, SP 163-176. In contrast, 
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Figure 3.  The Ag specificity of T cell clones specific for PDC-E2 pep- 
tide 163-182 and the effect of mAbs to cell surface molecules on the prolifer- 
ative response of T cell clones. (A) T-pep-2-1 was cultured with PDC-E2 
peptide 163-182 (1-20 gg/ml), OVA (20 gg/ml), and OGDC (20 gg/ml) 
in the presence of autologous irradiated PBMCs.  After 3 d of culture, 
[3H]TdR was pulsed for 10 h, and [3H]TdR incorporation was measured. 
T-pep-2-1 proliferated in response to PDC-E2 peptide 163-182 in a dose- 
dependent manner, but not to OVA or OGDC. (B) T-pep-2-1 was simi- 
larly cultured with PDC-E2 peptide 163-182 (10 gg/ml) in the presence 
of various mAbs: anti-CD3, anti-CD4, anti-CD8, anti-HLA class I, anti- 
DP, anti-DQ, and anti-DR. After 3 d of culture, [3H]TdR incorporation 
was similarly  measured, mAbs such as anti-CD3, anti-CD4, and anti-HLA 
DR. inhibited the proliferative response of T-pep-2-1 to PDC-E2 peptide 
163-182. The proliferative response of other T cell clones specific  for PDC-E2 
peptide 163-182 were also studied, and their results were similar to those 
with T-pep-2-1. 
only one peptide, SP 163-176 substituted with alanine at po- 
sition 172, did not inhibit the proliferative response of clone 
T-pep-2-2. Similar competition experiment results were ob- 
tained for clones T-pep-11-1 and T-pep-11-2. These results in- 
dicated that amino acid D  at position 172 is a critical MHC- 
binding site for all T  cell clones tested, but that the amino 
acids critical for the recognition by TCR  differed in each T 
cell clone. 
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Figure 4.  HLA restriction of T cell clones specific for PDE-E2 peptide 
163-182. T-pep-2-1 was cultured with PDC-E2 peptide 163-182 (20 #g/ml) 
(left bar) or without any peptide (right bar) in the presence of irradiated 
allogeneic PBMCs derived from seven healthy controls with various HLA 
haplotypes: S.S., T.M., K.H., E.B., N.F., H.I., and K.Y. After 3 d of cul- 
ture, [3H]TdR was pulsed for 10 h, and [3H]TdR incorporation was mea- 
sured. All of the other T cell clones specific for PDC-E2 peptide 163-182 
were similarly studied for their proliferative response to PDC-E2 peptide 
163-182. All T cell clones proliferated in response to peptide 163-182 in 
the presence of allogeneic PBMCs having the HLA DRB4 0101 haplotype. 
Proliferative Response ofT Cell Clones to Other Peptides That 
Have Amino Acid Sequence Homology with Human PDC-E2 
I63-176.  We next studied the proliferative response ofT cell 
clones to five different self and nonself peptides: human PDC- 
E2 36-49 (outer lipoyl domain), P. putida BCOADC  104-117, 
E.  coli PDC-E2  31-44/134-147/235-248,  human  glycogen 
phosphorylase/~ 354-367, and HLA DR  ot chain 82-95, which 
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Figure 5.  Minimal epitope mapping of T cell clones specific for PDC- 
E2 163-182. T-pep-2-1 was cultured with SP 162-175, 163-175, 164-177, 
164-176, 163-176, 163-177, 161-177, or 163-182 in the presence of autolo- 
gous irradiated PBMCs. After 3 d of culture, [3H]TdR was pulsed for 10 
h, and [3H]TdR incorporation was measured.  All of other T cell clones 
specific  for PDC-E2 peptide 163-182 were similarly studied for their prolifer- 
ative response to each peptide. The minimal epitopes of all T cell clones 
were mapped to 163-176. 
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Proliferation of the T cell clones in response to alanine- or 
serine-substituted  peptides of PDC-E2 163-176. T-pep-2-1 was cultured 
with alanine-substituted peptide 163-176 at positions 163, 164, 165, 166, 
168, 169, 170, 171, 172, 173, 175, and 176, and with serine-substituted 
peptide 163-176 at positions 167 and 174. After 3 d of culture, [3H]TdR 
was pulsed for  10 h,  and the [3H]TdR incorporation was measured. 
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Figure 8.  Competition for antigen presentation between nonstimula- 
tory single alanine- or serine-substituted peptide analogues and original 
PDC-E2 peptide 163-176. T-pep-2-2  was first cultured with 40 or 80 #g/ml 
nonstimulatory peptide analogues (alanine-substituted peptides at posi- 
tions 166, 168, 170, 171, 172, and 173 and serine-substituted peptide at 
position  167) in the presence of autologous  irradiated PBMCs for 1 h. 
The original PDC-E2 peptide  163-176 was then added to the culture at 
a final concentration of 1 #g/ml. After 3 d of culture, [3H]TdR was pulsed 
for 10 h, and [3H]TdR incorporation was measured. [7771, competitor 40 
/xg/ml; [----1, competitor  80 #g/ml. 
share amino acid sequence homology with human PDC-E2 
163-176 in ratios of 11:14, 9:14,  5:14,  4:14,  and 6:14,  respec- 
tively (40).  Human PDC-E2 36-49, P. putida BCOADC 104- 
117, and E. coli PDC-E2 31-44/134-147/235-248 have EXDK 
sequences, and the other two peptides have DXDK or AXDK 
sequences.  As shown in Fig. 9,  all T  cell clones proliferated 
in response to human PDC-E2 36-49, which has EXDK se- 
quences and corresponds to the outer lipoyl domain of human 
PDC-E2.  One  T  cell clone,  T-pep-ll-2,  proliferated  in re- 
sponse to E. coli PDC-E2 31-44/134-147/235-248,  but not 
P. putida BCOADC 104-117, which have EXDK sequences. 
The other two T  cell clones, T-pep-2-2 and T-pep-11-1,  did 
not proliferate in response to these two peptides with EXDK 
sequences.  None of the T cell clones proliferated in response 
to human  glycogen phosphorylase/~ 354-367 or HLA DR 
c~ chain  82-95. 
Discussion 
Although mitochondrial Ags are present in the inner mem- 
branes of mitochondria  in every cell type in  the body,  the 
autoimmune  process in  PBC is restricted  to  the liver;  the 
infiltration of T cells, B cells, and macrophages is distributed 
mainly  around  the  biliary ductular  tissues in  the liver  (2, 
10-12).  This  organ-specific  autoimmune  process  in  PBC, 
though non-organ-specific target  self Ags are present, may 
be explained by the specific expression of mitochondrial Ags 
in addition to HLA DR. and DQ molecules on or near the 
luminal surface of biliary epithelial cells in the liver (13-17). 
B  and  T  cells  infiltrating  the  liver  produce  AMAs  and 
proliferate in response to PDC or OGDC in vitro,  respec- 
tively (14,  18-20). E2, Elc~,  and EI~ components and pro- 
tein X of PDC and E2 components of OGDC and BCOADC 
have also been identified as autoantigens recognized by AMAs 
(3-9). 
Based on these observations, it is very likely that the im- 
mune response to mitochondrial Ags, such as PDC, OGDC, 
and BCOADC in the liver, plays a central role in the patho- 
genesis  of PBC.  Therefore,  the  identification  of the  im- 
munodominant  autoepitopes and HLA molecules involved 
in  the  immune  response to mitochondrial  Ags could pos- 
sibly clarify the pathogenesis of PBC and establish therapeutic 
strategies to prevent the occurrence or the progression of PBC. 
However, thus far, there have been no reports on the T  cell 
Figure 7.  The amino acids of PDC-E2  163-176 crit- 
ical for the recognition by TCR or for the binding  to HLA 
DRB4 0101. Shaded squares indicate the amino acids that 
abolish the proliferative response of T cell clones by ala- 
nine or serine substitution. 
1840  Immunodominant T  Cell Autoepitope  of PDC-E2  in Primary  Biliary Cirrhosis NO  Jbnt lgen 
hmma  PDC-E2  16~-176 
hv~Bn  PDC-B2  36-49 
P.putide  BCOADC  104-117 
B. coll  PIX:-B2  31-44/134-147/235-248 
h~=  glycogen  pholphoEylame~  354-36"7 
DR=  chain  82-95 
GDLLAE  IBTDKATI 
GDL  ILEVBTDKATV 
DEI3.Jt,  T I  ]~L'DK I D I 
EQSLI TV~GDKASM 
B 
T-pep-2-2 
'  2~"  400"  1~0"  8~"  lOGO 
(r 
C 
T-pep-11-1  T-pep-11-2 
￿9  ,  ￿9  ,  .  ,  ￿9  ,  -  ,  . 
1Q(IO  2000  3000  4000  5000 
(r  (e~ml 
Figure 9.  The cross-reactivity of T cell clones specific for PDC-E2 peptide 163-176 with other self or non-self  peptides. (A) T-pep-2-2 was cultured 
with various self or non-self  peptides (human PDC-E2 36-49, P. putida BCOADC 104-117, E. coli PDC-E2 31-44/134-147/235-248,  human glycogen 
phosphorylase ~ 354-367 and HLA DR oe chain 82-95) (20-80 gtg/ml) in the presence of autologous irradiated PBMCs. After 3 d of culture, [3H]TdR 
was pulsed for 10 h, and [3H]TdR incorporation was measured. T-pep-11-1 (B) and T-pep-11-2 (C) were similarly studied for their proliferative re- 
sponse to various self and non-self antigens. 
autoepitopes of mitochondrial Ags at the molecular level or 
their MHC restriction molecules (14, 18-20). 
We previously found that PDC-specific T  cells are cir- 
culating in the peripheral blood of patients with PBC, and 
that all T cell lines specific for PDC proliferate in response 
to  PDC-E2,  indicating  that  PDC-E2  contains  the  im- 
munodominant T cell autoepitopes of PDC (data not shown). 
Therefore, in the present study, we tried to generate PDC- 
E2-specific T cell clones by using various peptides covering 
PDC-E2 as selecting Ags. The characterization of six PDC- 
E2-specific T cell clones successfully  generated in the present 
study showed the following: (a) minimal T cell autoepitopes 
of T cell clones specific for PDC-E2 were all located on the 
same region of PDC-E2 peptide  163-176 (GDLLAEIETD- 
KATI),  which corresponds  to the inner lipoyl domain of 
human PDC-E2; (b) all T cell clones specific  for human PDC- 
E2 163-176 are restricted by the same MHC molecule, HLA 
DRB4 0101; (c) E, D, and K at positions  170, 172, and 173 
are common essential amino acid residues for this T cell epi- 
tope; (d) all T cell clones specific for human PDC-E2 163- 
176 react to PDC-E2 peptide 36-49 (GDLIAEVETDKAT), 
which corresponds to the outer lipoyl domain of human PDC- 
E2; (e) one T cell clone (T-pep-11-2) cross-reacts with exoge- 
nous Ags, such as E. coli PDC-E2 peptide 31-44/134-147/235- 
248 (EQSLITVEGDKASM),  which has EXDK sequences, 
but  none  of the T  cell clones  cross-react with P. putida 
BCOADC peptide 104-117 (DELLATIETDKIDI), which has 
EXDK sequences; and (f) none of the T cell clones cross- 
react with self-peptides derived from human glycogen phos- 
phorylase B or HLA DR ot chain, which share amino acid 
homology with human PDC-E2 163-176 but do not have 
EXDK sequences. 
It has been hypothesized that PBC may have a bacterial 
etiology because of the high incidence of recurrent urinary 
tract infection in patients with PBC (1, 2, 8). Furthermore, 
the sera from patients with PBC react with both human PDC- 
E2 and E. coli PDC-E2 (8, 9). This is because PDC-E2 pep- 
tides are evolutionarily highly conserved among different spe- 
cies, especially in their lipoic acid-binding sites (4-6). Thus, 
a mechanism of molecular mimicry has been proposed as a 
possible cause of PBC (40). In this hypothesis, the T cells 
first recognize the lipoyl domain orE. coli PDC-E2 containing 
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EGDKA sequences. Then, these T ceils cross-react with self 
peptides containing AVDKA sequences from HLA DR c~ 
chain or ETDKA sequences from human PDC-E2 by abet- 
randy expressed class II HLA molecules on biliary epithelial 
cells (13-17). Finally, this initiates the autoimmune cascade 
leading to the destruction of the bile ducts in which AMAs 
and/or autoreactive T cells specific  for mitochondrial Ags may 
play a pathogenic role. At this stage, the autoimmune pro- 
cess takes place in the absence of the exogenous Ags, such 
as E. coli PDC-E2, which initiated the immune response. In 
some animal models of autoimmune diseases, such as ex- 
perimental allergic encephalomyelitis  and autoimmune oopho- 
ritis, the mechanism of molecular mimicry has been proven 
to be operative in vivo (41-47). 
In this study, we demonstrated the presence of a T  cell 
clone specific  for human PDC-E2 163-176 (GDLLAEIETD- 
KATI) that cross-reacts with the lipoic acid-binding site of 
E. coli PDC-E2 (EQSLITVEGDKASM).  This is the proof 
that molecular mimicry between human and E. coli PDC-E2 
can be operative at the T  cell donal level in PBC.  On the 
other hand, none of T cell clones specific  for PDC-E2 cross- 
reacted with HLA DR c~ chain peptide 82-95 (QGALAN- 
IAVDKANL) or human glycogen phosphorylase 3 peptide 
354-367 (LVDLERMDWDKAWD),  which share amino acid 
homology with PDC-E2 but have no EXDK sequences. This 
finding indicates that the presence of amino acid homology 
per se is not sufficient to provoke the cascade of molecular 
mimicry. Moreover, it is important that clone T-pep-11-2 cross- 
reacted with E. coli PDC-E2 (EQSLITVEGDKASM),  but 
not with P. putida  PDC-E2 (DELLATIETDKIDI), which 
not only has EXDK sequences, but also has greater amino 
acid homology with human PDC-E2 163-176 than E.  coli 
PDC-E2(EQSLITVEGDKASM).  To explain this phenome- 
non of cross-reactivity at the T  cell donal level, it will be 
necessary to dissect the molecular mechanism of the MHC 
class II-peptide-TCK interaction. 
The recognition of peptide fragments in the context of 
class II MHC molecules by T cells is a central event in the 
development of the immune response (48-50).  Proteolytic 
fragments of peptides processed  by APCs that match the phys- 
iochemical character of the peptide-binding grooves formed 
by ot and 3 chains of class II MHC molecules are expressed on the surface of APCs and are recognized by T cells (48-50). 
The structural motifs of peptides capable of binding to HLA 
DR have been determined based on the peptide sequences 
eluted from purified DR complexes (51, 52) or phage pep- 
tide libraries (53, 54). These reports indicated that only cer- 
tain residues are involved in allele-specific peptide binding, 
whereas the other residues are promiscuous (51-54). An anal- 
ysis of the crystal structure ofHLA DRB1 0101 protein com- 
plexed with an influenza virus peptide demonstrated the exact 
structural explanation for the MHC class II-peptide-TCR 
interaction at the molecular level (50). Because polymorphic 
residues of DR alleles are scattered within the peptide-binding 
grooves, different DR molecules are capable of binding pep- 
tides with different structural motifs, and this phenomenon 
contributes to the HLA-linked polymorphism of the immune 
response: DRB1 0405 confers increased susceptibility to rheu- 
matoid arthritis, but not to insulin autoimmune syndrome, 
whereas DRB1 0406 conversely confers susceptibility to the 
latter but not to the former. 
To date, motifs for binding peptides have been reported 
in various DR molecules, including DR1 (DRB1 0101), DR2 
(DRB1 1501), DR3 (DRB1 0301), DR4 (DRB1 0401, DRB1 
0405, DRB1 0406), DR11 (DRB1 1101), DR7 (DRB1 0701), 
and DR8 (DRB1 0801) (24, 52-55), indicating that two or 
three hydrophobic amino acids are necessary for the binding 
of the peptide to HLA hydrophobic pockets. However, no 
peptide-binding motif of HLA DRB4 0101 has been reported. 
Although the precise analysis of the peptide-binding motif 
of HLA  DRB4 0101 is now underway using HLA DRB4 
0101-transfected L cells and various modified peptides based 
on PDC-E2 peptide 163-176 (GDLLAEIETDKATI), our pre- 
liminary study indicates that LXXIXXD is an HLA DRB4 
0101-binding motif. If this is the case, the E and K at posi- 
tions 170 and 173 may be crucial TCR-binding sites, and the 
amino acid at position 169 (I for human and P. ioutida PDC- 
E2 and V for E. coli PDC-E2) may have an important effect 
on the structure of the TCR-binding site. The rationale for 
the development of molecular mimicry at the T  cell clonal 
level is now under investigation using T cell clones specific 
for human PDC-E2 163-176 (GDLLAEIETDKATI) and/or 
E. coli PDC-E2 (EQSLITVEGDKASM) and various peptides 
that share amino acid homology with these peptides. 
In Caucasians, PBC has been reported to be associated with 
HLA DR3 (56), HLA DRw8 (57),  and possibly HLA DR4 
(58).  An association with HLA DR2 (59) and DP B1 0501 
(60) has been reported in Japanese patients with PBC. In other 
studies, no such associations were found with HLA Ags (61). 
Thus,  no consensus seems to exist concerning the associa- 
tions between PBC and HLA.  In the present study, all T 
cell clones from four different patients with PBC recognized 
human PDC-E2  163-176 in the context of the same HLA 
allele,  HLA DRB4 0101, indicating that PDC-E2 peptide 
163-176 plays a central role in at least all patients with PBC 
who have the HLA DRB4 0101 allele. The ratio of HLA 
DRB4 0101 positivity among patients with PBC is ~77%. 
This is similar to the control Japanese population (62), indi- 
cating that the possession  of HLA DRB4 0101 may not be 
a genetic predisposition for PBC.  However, in contrast to 
the highest degree of polymorphism of HLA DRB1, poly- 
morphism ofHLA DRB4 0101 has not been reported. There- 
fore, it is possible that the HLA DRB4 0101-binding PDC-E2 
peptide identified in the present study could provide impor- 
tant information for the development of peptide-specific im- 
munotherapy in the majority of patients with PBC who have 
an HLA DRB4  0101 allele. 
Interestingly, the T cell epitope of PDC-E2 peptide 163- 
176 almost completely overlaps with the B cell epitopes that 
were identified in the inner lipoyl domain of PDC-E2 (PDC- 
E2  165-184 with lipoic acid located at K  at 174) (7-9).  In 
addition, all T cell clones specific for PDC-E2 peptide 163-176 
cross-reacted with PDC-E2 peptide 36-49, which corresponds 
to the outer lipoyl domain of PDC-E2. This PDC-E2 outer 
lipoyl domain was also shown to be the immunodominant 
B cell epitope of PDC-E2 that cross-reacts with the B cell 
epitope of the inner lipoyl domain of PDC-E2  (7-9).  Re- 
cently, "universal" T cell epitopes of certain viruses have been 
found to be located near the B cell epitopes, indicating that 
the regions containing both T and B cell epitopes can be highly 
immunogenic (37,  63-66).  Although there have been no 
reports theoretically showing the exact relationship between 
T  and B cell epitopes of self Ags, our results may indicate 
the possibility that peptides of self Ags containing both T 
and B cell epitopes can be highly immunogenic autoepitopes 
that cause various autoimmune responses.  In this aspect, we 
speculate that  the region corresponding to or overlapping 
PDC-E2 peptide  163-176 can also be a T  cell autoepitope 
in the context of MHC class II molecules other than the HLA 
DRB4 0101 allele. We are now trying to identify the T cell 
autoepitopes in patients with PBC who have no HLA DRB4 
0101  allele. 
In conclusion,  the present  study not  only is  a definite 
demonstration of an immunodominant T  cell autoepitope 
of PDC-E2, but it is also a demonstration of the molecular 
mimicry that is operative at the T  cell clonal level in PBC. 
Based on these findings, it is considered possible to develop 
a strategy for the peptide-specific immunotherapy in PBC. 
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